A particle-enhanced turbidimetric immunoassay for quantitative determination of orosomucoid in urine: Development, validation and reference values

Clinical Chemistry and Laboratory Medicine

Volumn 42, Issue 10, 2004, Pages 1168-1177

  Christiansen, Merete Skovdal ^a   Blirup Jensen, Søren ^b   Foged, Lise ^a   Larsen, Marianne ^b   Magid, Erik ^a  

^a AMAGER HOSPITAL   (Denmark)

^b AGILENT TECHNOLOGIES   (United States)

Author keywords

Cardiovascular mortality; Certified reference material; Particle enhanced turbidimetry; Reference values; Urinary orosomucoid excretion

Indexed keywords

CREATININE; OROSOMUCOID; PLASMA PROTEIN;

ACCURACY; ADULT; ARTICLE; AUTOMATION; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; MALE; MEDICAL ASSESSMENT; MICROPARTICLE ENZYME IMMUNOASSAY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; REFERENCE VALUE; SENSITIVITY ANALYSIS; TURBIDIMETRY; URINALYSIS; URINARY EXCRETION; VALIDATION PROCESS;

ADULT; CALIBRATION; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; IMMUNOASSAY; MALE; NEPHELOMETRY AND TURBIDIMETRY; OROSOMUCOID; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SERUM ALBUMIN;

EID: 8344242149     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2004.237     Document Type: Article

References (48)

1. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995;44:1303-9.
2. Jarrett RJ, Viberti GC, Argyropoulos A, Hill RD, Mahmud U, Murrells TJ. Microalbuminuria predicts mortality in non-insulin-dependent diabetics. Diabet Med 1984; 1:17-9.
3. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356-60.
4. Neil A, Hawkins M, Potok M, Thorogood M, Cohen D, Mann J. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 1993;16:996-1003.
5. Schmitz A, Vaeth M. Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients. Diabet Med 1988;5:126-34.
6. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995;346:1080-4.
7. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, et al. Nephropathy in diabetes. Diabetes Care 2004;27 Suppl 1:S79-S83.
8. Christiansen MS, Hommel E, Magid E, Feldt-Rasmussen B. Orosomucoid in urine predicts cardiovascular and over-all mortality in patients with type II diabetes. Diabetologia 2002;45:115-20.
9. Poortmans JR, Haralambie G. Biochemical changes in a 100 km run: proteins in serum and urine. Eur J Appl Physiol Occup Physiol 1979;40:245-54.
10. Tencer J, Thysell H, Grubb A. Analysis of proteinuria: reference limits for urine excretion of albumin, protein HC, immunoglobulin G, kappa- and lambda-immunoreactivity, orosomucoid and alpha 1-antitrypsin. Scand J Clin Lab Invest 1996;56:691-700.
11. Ito S, Tsuda A, Momotsu T, Igarashi K, Kasahara S, Satoh K, et al. Urinary orosomucoid excretion rate in patients with non-insulin-dependent diabetes mellitus. Acta Endocrinol (Copenh) 1989;120:584-90.
12. Vittinghus E. Preanalytical handling of stored urine samples, and measurement of beta 2-microglobulin, orosomucoid, albumin, transferrin and immunoglobulin G in urine by enzyme-linked immunosorbent assays (ELISA). Scand J Clin Lab Invest 1990;50:843-9.
13. Blirup-Jensen S. Protein standardization III: method optimization. Basic principles for quantitative determination of human serum proteins on automated instruments based on turbidimetry or nephelometry. Clin Chem Lab Med 2001;39:1098-109.
14. Newman DJ, Henneberry H, Price CP. Particle enhanced light scattering immunoassay. Ann Clin Biochem 1992;29(Pt 1):22-42.
15. Price CP, Spencer K, Whicher J. Light-scattering immunoassay of specific proteins: a review. Ann Clin Biochem 1983;20(Pt 1):1-14.
16. Blirup-Jensen S. Protein standardization I: protein purification procedure for the purification of human prealbumin, orosomucoid and transferrin as primary protein preparations. Clin Chem Lab Med 2001;39:1076-89.
17. Weeke B. Crossed immunoelectrophoresis. In: Axelsen NH, Kroll J, Weeke B, editors. A manual of quantitative immunoelectrophoresis. Methods and applications. Oxford: Blackwell Scientific Publications, 1973:47-56.
18. Baudner S, Bienvenu J, Blirup-Jensen S, Carlström A, Johnson AM, Milford-Ward A, et al. The certification of a matrix reference material for immunochemical measurement of 14 human serum proteins CRM 470. EUR 15243 EN ed. Community Bureau of Reference, Commission of the European Communities, 1993:1-186.
19. Blirup-Jensen S, Johnson AM, Larsen M. Protein standardization IV: value transfer procedure for the assignment of serum protein values from a reference preparation to a target material. Clin Chem Lab Med 2001;39:1110-22.
20. Whicher JT, Ritchie RF, Johnson AM, Baudner S, Bienvenu J, Blirup-Jensen S, et al. New international reference preparation for proteins in human serum (RPPHS). Clin Chem 1994;40:934-8.
21. NCCLS Approved Guideline EP9-A. Method comparison and bias estimation using patient samples. Wayne, PA: National Committee for Clinical Laboratory Standards, 1995;15.
22. NCCLS Approved Guideline EP5-A. Evaluation of precision performance of clinical chemistry devices. Wayne, PA: National Committee for Clinical Laboratory Standards, 1999;19.
23. NCCLS Proposed Guideline EP6-P. Evaluation of the linearity of quantitative analytical methods. Wayne, PA: National Committee for Clinical Laboratory Standards, 1986;18.
24. NCCLS Approved Guideline EP15-A. User demonstration of performance for precision and accuracy. Wayne, PA: National Committee for Clinical Laboratory Standards, 2000;18.
25. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
26. Dybkaer R, Solberg HE. International Federation of Clinical Chemistry (IFCC). Approved recommendation (1987) on the theory of reference values. Part 6. Presentation of observed values related to reference values. Clin Chim Acta 1987;170:S33-S42.
27. Solberg HE. International Federation of Clinical Chemistry (IFCC). Approved recommendation (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits. Clin Chim Acta 1987;170:S13-S32.
28. Du Bois D, Du Bois E. A formula to estimate the approximate surface area if height and weight be known. Arch Int Med 1916;17:863-71.
29. Schmid K. Human plasma alpha 1-acid glycoprotein - biochemical properties, the amino acid sequence and the structure of the carbohydrate moiety, variants and polymorphism. Prog Clin Biol Res 1989;300:7-22.
30. Lögdberg L, Wester L. Immunocalins: a lipocalin sub-family that modulates immune and inflammatory responses. Biochim Biophys Acta 2000;1482:284-97.
31. Jensen H, Henriksen K. Proteinuria in non-renal infectious diseases. Acta Med Scand 1974;196:75-82.
32. Pang JX, Ginanni N, Dongre AR, Hefta SA, Opitek GJ. Biomarker discovery in urine by proteomics. J Proteome Res 2002;1:161-9.
33. Nielsen SH, Petersen JS, Magid E. Albuminuria in ischemic heart disease. Scand J Clin Lab Invest Suppl 1999;230:143-52.
34. Tencer J, Thysell H, Andersson K, Grubb A. Long-term stability of albumin, protein HC, immunoglobulin G, kappa- and lambda-chain-immunoreactivity, orosomucoid and alpha 1-antitrypsin in urine stored at -20 degrees C. Scand J Urol Nephrol 1997;31:67-71.
35. Hemmingsen L, Skaarup P. The 24-hour excretion of plasma proteins in the urine of apparently healthy subjects. Scand J Clin Lab Invest 1975;35:347-53.
36. Kordonouri O, Jorres A, Muller C, Enders I, Gahl GM, Weber B. Quantitative assessment of urinary protein and enzyme excretion - a diagnostic programme for the detection of renal involvement in type I diabetes mellitus. Scand J Clin Lab Invest 1992;52:781-90.
37. Khalaf AN, Bocker J, Kerp L, Petersen KG. Urine screening in outdoor volunteers: day versus night versus 24 hour collection. Eur J Clin Chem Clin Biochem 1991;29:185-8.
38. Cohen DL, Close CF, Viberti GC. The variability of overnight urinary albumin excretion in insulin-dependent diabetic and normal subjects. Diabet Med 1987;4:437-40.
39. Howey JE, Browning MC, Fraser CG. Selecting the optimum specimen for assessing slight albuminuria, and a strategy for clinical investigation: novel uses of data on biological variation. Clin Chem 1987;33:2034-8.
40. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
41. Johnsson E, Haraldsson B. Addition of purified orosomucoid preserves the glomerular permeability for albumin in isolated perfused rat kidneys. Acta Physiol Scand 1993;147:1-8.
42. Sörensson J, Matejka GL, Ohlson M, Haraldsson B. Human endothelial cells produce orosomucoid, an important component of the capillary barrier. Am J Physiol 1999;276:H530-H534.
43. Sörensson J, Ohlson M, Björnson A, Haraldsson B. Orosomucoid has a cAMP-dependent effect on human endothelial cells and inhibits the action of histamine. Am J Physiol Heart Circ Physiol 2000;278:H1725-H1731.
44. Hochepied T, Berger FG, Baumann H, Libert C. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev 2003;14:25-34.
45. Daemen MA, Heemskerk VH, van't Veer C, Denecker G, Wolfs TG, Vandenabeele P, et al. Functional protection by acute phase proteins alpha(1)-acid glycoprotein and alpha(1)-antitrypsin against ischemia/reperfusion injury by preventing apoptosis and inflammation. Circulation 2000;102:1420-6.
46. Hochepied T, Van Molle W, Berger FG, Baumann H, Libert C. Involvement of the acute phase protein alpha 1-acid glycoprotein in nonspecific resistance to a lethal gram-negative infection. J Biol Chem 2000;275:14903-9.
47. Muchitsch EM, Teschner W, Linnau Y, Pichler L. In vivo effect of alpha 1-acid glycoprotein on experimentally enhanced capillary permeability in guinea-pig skin. Arch Int Pharmacodyn Ther 1996;331:313-21.
48. Muchitsch EM, Auer W, Pichler L. Effects of alpha 1-acid glycoprotein in different rodent models of shock. Fundam Clin Pharmacol 1998;12:173-81.